Weekly note 11 Module 11

1

4

Weekly Notes – Chapter 6: Module 6

Mood Disorders and the Neurotransmitter Networks. Norepinephrine and γ-Aminobutyric Acid (GABA)

Stahl's Essential Psychopharmacology, Fifth Edition | Textbook pages 244–282

Description of Mood Disorders – p. 244

Mood disorders encompass depression, mania, and combinations of these. In major depression, the symptoms are five; in mania, the symptoms are elevated, expansive, or irritable mood in addition to other symptoms. Mood disorders are not just about mood, but include several symptoms and brain circuits. Chapter 6 emphasizes that, clinically, the provider recognizes the patient's overall diagnosis from the pattern and course of symptoms. Neurobiologically, the provider can then "deconstruct" that diagnosis into individual symptoms and consider the brain circuits and neurotransmitters that may be contributing to each symptom.

Mood Spectrum – p. 244

Mood disorders can be viewed along a spectrum rather than as completely separate categories. Mood disorders are on a continuum from depression to hypomania and mania. Unipolar depression refers to the depressive pole, and bipolar disorders refer to manic/hypomanic and depressive episodes. Mixed features are when depressive and manic symptoms are present in the same episode. A depressive episode with mixed features comprises the full depressive syndrome together with numerous manic/hypomanic symptoms. A manic or hypomanic episode with mixed features comprises the full manic/hypomanic syndrome together with significant depressive symptoms. This reinforces the idea that mood disorders are dimensional and that a patient's symptom pattern can go along the spectrum over time.

Distinguishing Unipolar Depression from Bipolar Depression – p. 249

It can be hard to tell unipolar depression from bipolar depression during a depressive episode, as they share many of the same symptoms. History of mania or hypomania is important. History of family members with bipolar disorder, substance abuse, early onset, presence of psychotic symptoms, irritability, and brief but frequent depressive episodes may be clues to bipolar depression. The chapter also ranks mood and psychotic disorders on a broader continuum. Instead of assuming that schizophrenia, schizoaffective disorder, bipolar disorder, and depression always exist as absolutely separate biological categories, overlapping symptoms may occur. The patient's pattern of mood symptoms, psychosis, timing, severity, and illness course facilitates determining the clinical diagnosis.

Mixed Features: Are Mood Disorders Progressive? – p. 251

Mood disorders can become recurrent unipolar depression, mixed features, bipolar disorder, and eventually treatment-resistant. Mixed features correlate with a more complicated course and heightened clinical risk. One suggested progression is from recurring unipolar depressive episodes to depression with mixed features, then toward a bipolar-spectrum presentation, and eventually toward treatment resistance. This concept highlights the importance of recognizing subtle manic or hypomanic symptoms rather than assuming that every depressive presentation is purely unipolar. However, early diagnosis and management may help prevent progression, though this remains a hypothesis.

Neurobiology of Mood Disorders – p. 252

Mood disorders are related to brain circuits and neurotransmitter systems. Norepinephrine, dopamine, serotonin, glutamate, and GABA are all important systems. These systems communicate with mood-related, cognitive-related, sleep, motivational, and other brain circuits. This broader model facilitates explaining why mood disorders are heterogeneous. Different patients may exhibit different combinations of circuit dysfunction, neurotransmitter changes, environmental stressors, and biological vulnerabilities even when they meet criteria for the same diagnosis.

Neurotransmitters – p. 252

Norepinephrine is synthesized from the precursor tyrosine and is controlled by the enzymes VMAT2 and NET, and by α and β receptors. Glutamate is the primary excitatory neurotransmitter and is converted to the primary inhibitory one, GABA, by the enzyme GAD. GAT, GABA-T, and GABA receptors (GABA-A, GABA-B, and GABA-C) control GABA activity. This chapter also separates synaptic, benzodiazepine-sensitive GABAA receptors from extrasynaptic, benzodiazepine-insensitive GABAA receptors. Synaptic receptors contain a gamma subunit, mediate phasic inhibition, and can be modulated by benzodiazepines. Extrasynaptic receptors often contain a delta subunit and contribute to tonic inhibition. Neuroactive steroids can act as positive allosteric modulators at GABAA receptors, including extrasynaptic receptors. This is especially significant to the chapter's discussion of depression and postpartum depression, where altered neurosteroid/GABA signaling may influence neuronal excitability and mood-related circuits.

The Monoamine Hypothesis of Depression – p. 264

The old monoamine theory is that depression is due to a low level of Norepinephrine, serotonin, or dopamine. Nevertheless, the theory of a simple monoamine deficiency is not as strongly supported as a more complete explanation for depression. The hypothesis is useful; however, it is incomplete. A minimal shortage of serotonin, Norepinephrine, or dopamine cannot fully describe depression. Medication-induced changes at monoamine transporters or receptors can occur immediately, while meaningful clinical progress often develops afterward. In addition, not every patient responds to a treatment that increases monoamine signaling. These explanations suggest that downstream adaptations are important.

The Monoamine Receptor Hypothesis and Neurotrophic Factors – p. 264

One major hypothesis is that decreased monoamine activity triggers a compensatory change in postsynaptic receptors; this is called the receptor hypothesis. Downstream processes such as gene expression and neurotrophic factors, including BDNF, have also drawn attention. Treatment may thus involve more than increasing neurotransmitter levels; successful treatment may also reinstate downstream signaling, neurotrophic support, and neural networks' capacity to adapt.

Beyond Monoamines: Neuroplasticity and Neuroprogression Hypothesis of Depression – p. 266.

Within hours or days, antidepressants can elevate monoamines, but it may take several weeks for clinical improvement to occur. This has shifted focus toward receptor changes, BDNF, neuroplasticity, stress and inflammation, genetics, and environmental factors. Decreased levels of neurotrophic factors could contribute to synapse loss, neuronal damage, and neuroprogression. Neuroprogression describes the possibility that recurring or poorly treated mood episodes may be correlated with progressively greater biological and functional impairment. In this model, impaired plasticity, chronic stress, inflammation, and reduced neurotrophic support can strengthen one another and contribute to persistent or recurrent illness. This framework elaborates the understanding of depression from a neurotransmitter imbalance to a disorder of interconnected neural, endocrine, immune, genetic, and environmental systems.

Symptoms and Circuits in Mood Disorders – p. 277

Symptoms can be linked to particular brain circuits. Different circuits and neurotransmitters are implicated in depression and mania. Positive affect is linked to dopamine release, while serotonin and norepinephrine release is linked to negative affect and other symptoms. Examples of circuit localization include the prefrontal cortex in concentration and executive function; the prefrontal cortex and nucleus accumbens in reduced attention and reward; the hypothalamus in sleep-related indicators; and broader prefrontal/striatal/reward pathways in fatigue and reduced energy. The text highlights that these diagrams are simplified. A circuit includes various neurons, and activity may increase in some parts, decrease in others, remain normal in others, or fluctuate over time. This complexity helps explain mixed symptoms and changes in presentation across episodes.

Symptom-Based Treatment Selections – p. 279

Residual symptoms can be identified; circuits likely to be malfunctioning can be matched to the identified symptoms; the neurotransmitter associated with the identified circuit can be determined; and appropriate pharmacological mechanisms can be chosen. Fatigue and concentration problems can be related to Norepinephrine and dopamine, and sleep disturbances to serotonin, GABA, and histamine. The model supports individualized psychopharmacology because two patients with similar diagnoses may require different combinations of mechanisms. The explanation does not argue that the symptom-based algorithm has been shown to be superior to every other approach. Rather, it presents the approach as consistent with neurobiological reasoning and the clinical goal of treating the whole patient to remission rather than accepting an incomplete response.

Summary – p. 282

There are many different mood disorders: depression, mania, and mixed. It is important to identify unipolar, bipolar, and mixed presentations accurately. New theories go beyond monoamines to include neurotrophic factors, neuroplasticity, sleep, circadian rhythms, inflammation, stress, genetics, and the environment. Treatment now targets each symptom through specific brain circuits and neurotransmitter systems to achieve long-lasting remission. A key connection throughout chapter 6 is the correlation among symptoms, circuits, and neurotransmitters. Theoretically, individual symptoms can be linked to dysfunction in specialized neural networks, and multiple neurotransmitters regulate those networks. This provides a rationale for selecting individualized, symptom-based treatment. The overall goal is not simply improvement but sustained remission, with attention to remaining symptoms that may otherwise contribute to ongoing impairment or recurrence.

1

4

Weekly Notes – Chapter 6: Module 6

Mood Disorders and the Neurotransmitter Networks. Norepinephrine and γ-Aminobutyric Acid (GABA)

Stahl's Essential Psychopharmacology, Fifth Edition | Textbook pages 244–282

Description of Mood Disorders – p. 244

Mood disorders encompass depression, mania, and combinations of these. In major depression, the symptoms are five; in mania, the symptoms are elevated, expansive, or irritable mood in addition to other symptoms. Mood disorders are not just about mood, but include several symptoms and brain circuits. Chapter 6 emphasizes that, clinically, the provider recognizes the patient's overall diagnosis from the pattern and course of symptoms. Neurobiologically, the provider can then "deconstruct" that diagnosis into individual symptoms and consider the brain circuits and neurotransmitters that may be contributing to each symptom.

Mood Spectrum – p. 244

Mood disorders can be viewed along a spectrum rather than as completely separate categories. Mood disorders are on a continuum from depression to hypomania and mania. Unipolar depression refers to the depressive pole, and bipolar disorders refer to manic/hypomanic and depressive episodes. Mixed features are when depressive and manic symptoms are present in the same episode. A depressive episode with mixed features comprises the full depressive syndrome together with numerous manic/hypomanic symptoms. A manic or hypomanic episode with mixed features comprises the full manic/hypomanic syndrome together with significant depressive symptoms. This reinforces the idea that mood disorders are dimensional and that a patient's symptom pattern can go along the spectrum over time.

Distinguishing Unipolar Depression from Bipolar Depression – p. 249

It can be hard to tell unipolar depression from bipolar depression during a depressive episode, as they share many of the same symptoms. History of mania or hypomania is important. History of family members with bipolar disorder, substance abuse, early onset, presence of psychotic symptoms, irritability, and brief but frequent depressive episodes may be clues to bipolar depression. The chapter also ranks mood and psychotic disorders on a broader continuum. Instead of assuming that schizophrenia, schizoaffective disorder, bipolar disorder, and depression always exist as absolutely separate biological categories, overlapping symptoms may occur. The patient's pattern of mood symptoms, psychosis, timing, severity, and illness course facilitates determining the clinical diagnosis.

Mixed Features: Are Mood Disorders Progressive? – p. 251

Mood disorders can become recurrent unipolar depression, mixed features, bipolar disorder, and eventually treatment-resistant. Mixed features correlate with a more complicated course and heightened clinical risk. One suggested progression is from recurring unipolar depressive episodes to depression with mixed features, then toward a bipolar-spectrum presentation, and eventually toward treatment resistance. This concept highlights the importance of recognizing subtle manic or hypomanic symptoms rather than assuming that every depressive presentation is purely unipolar. However, early diagnosis and management may help prevent progression, though this remains a hypothesis.

Neurobiology of Mood Disorders – p. 252

Mood disorders are related to brain circuits and neurotransmitter systems. Norepinephrine, dopamine, serotonin, glutamate, and GABA are all important systems. These systems communicate with mood-related, cognitive-related, sleep, motivational, and other brain circuits. This broader model facilitates explaining why mood disorders are heterogeneous. Different patients may exhibit different combinations of circuit dysfunction, neurotransmitter changes, environmental stressors, and biological vulnerabilities even when they meet criteria for the same diagnosis.

Neurotransmitters – p. 252

Norepinephrine is synthesized from the precursor tyrosine and is controlled by the enzymes VMAT2 and NET, and by α and β receptors. Glutamate is the primary excitatory neurotransmitter and is converted to the primary inhibitory one, GABA, by the enzyme GAD. GAT, GABA-T, and GABA receptors (GABA-A, GABA-B, and GABA-C) control GABA activity. This chapter also separates synaptic, benzodiazepine-sensitive GABAA receptors from extrasynaptic, benzodiazepine-insensitive GABAA receptors. Synaptic receptors contain a gamma subunit, mediate phasic inhibition, and can be modulated by benzodiazepines. Extrasynaptic receptors often contain a delta subunit and contribute to tonic inhibition. Neuroactive steroids can act as positive allosteric modulators at GABAA receptors, including extrasynaptic receptors. This is especially significant to the chapter's discussion of depression and postpartum depression, where altered neurosteroid/GABA signaling may influence neuronal excitability and mood-related circuits.

The Monoamine Hypothesis of Depression – p. 264

The old monoamine theory is that depression is due to a low level of Norepinephrine, serotonin, or dopamine. Nevertheless, the theory of a simple monoamine deficiency is not as strongly supported as a more complete explanation for depression. The hypothesis is useful; however, it is incomplete. A minimal shortage of serotonin, Norepinephrine, or dopamine cannot fully describe depression. Medication-induced changes at monoamine transporters or receptors can occur immediately, while meaningful clinical progress often develops afterward. In addition, not every patient responds to a treatment that increases monoamine signaling. These explanations suggest that downstream adaptations are important.

The Monoamine Receptor Hypothesis and Neurotrophic Factors – p. 264

One major hypothesis is that decreased monoamine activity triggers a compensatory change in postsynaptic receptors; this is called the receptor hypothesis. Downstream processes such as gene expression and neurotrophic factors, including BDNF, have also drawn attention. Treatment may thus involve more than increasing neurotransmitter levels; successful treatment may also reinstate downstream signaling, neurotrophic support, and neural networks' capacity to adapt.

Beyond Monoamines: Neuroplasticity and Neuroprogression Hypothesis of Depression – p. 266.

Within hours or days, antidepressants can elevate monoamines, but it may take several weeks for clinical improvement to occur. This has shifted focus toward receptor changes, BDNF, neuroplasticity, stress and inflammation, genetics, and environmental factors. Decreased levels of neurotrophic factors could contribute to synapse loss, neuronal damage, and neuroprogression. Neuroprogression describes the possibility that recurring or poorly treated mood episodes may be correlated with progressively greater biological and functional impairment. In this model, impaired plasticity, chronic stress, inflammation, and reduced neurotrophic support can strengthen one another and contribute to persistent or recurrent illness. This framework elaborates the understanding of depression from a neurotransmitter imbalance to a disorder of interconnected neural, endocrine, immune, genetic, and environmental systems.

Symptoms and Circuits in Mood Disorders – p. 277

Symptoms can be linked to particular brain circuits. Different circuits and neurotransmitters are implicated in depression and mania. Positive affect is linked to dopamine release, while serotonin and norepinephrine release is linked to negative affect and other symptoms. Examples of circuit localization include the prefrontal cortex in concentration and executive function; the prefrontal cortex and nucleus accumbens in reduced attention and reward; the hypothalamus in sleep-related indicators; and broader prefrontal/striatal/reward pathways in fatigue and reduced energy. The text highlights that these diagrams are simplified. A circuit includes various neurons, and activity may increase in some parts, decrease in others, remain normal in others, or fluctuate over time. This complexity helps explain mixed symptoms and changes in presentation across episodes.

Symptom-Based Treatment Selections – p. 279

Residual symptoms can be identified; circuits likely to be malfunctioning can be matched to the identified symptoms; the neurotransmitter associated with the identified circuit can be determined; and appropriate pharmacological mechanisms can be chosen. Fatigue and concentration problems can be related to Norepinephrine and dopamine, and sleep disturbances to serotonin, GABA, and histamine. The model supports individualized psychopharmacology because two patients with similar diagnoses may require different combinations of mechanisms. The explanation does not argue that the symptom-based algorithm has been shown to be superior to every other approach. Rather, it presents the approach as consistent with neurobiological reasoning and the clinical goal of treating the whole patient to remission rather than accepting an incomplete response.

Summary – p. 282

There are many different mood disorders: depression, mania, and mixed. It is important to identify unipolar, bipolar, and mixed presentations accurately. New theories go beyond monoamines to include neurotrophic factors, neuroplasticity, sleep, circadian rhythms, inflammation, stress, genetics, and the environment. Treatment now targets each symptom through specific brain circuits and neurotransmitter systems to achieve long-lasting remission. A key connection throughout chapter 6 is the correlation among symptoms, circuits, and neurotransmitters. Theoretically, individual symptoms can be linked to dysfunction in specialized neural networks, and multiple neurotransmitters regulate those networks. This provides a rationale for selecting individualized, symptom-based treatment. The overall goal is not simply improvement but sustained remission, with attention to remaining symptoms that may otherwise contribute to ongoing impairment or recurrence.